SPRINT: lower blood pressure targets for many hypertensive

Original Title: A randomized trial of intensive versus standard blood-pressure control. Presenter: Wright JR Jr.

A systolic blood-pressure target lower than 120 over the standard 140 mm Hg reduces adverse events rates in non-diabetic patients at high cardiovascular risk, according to the SPRINT trial, but only at the expense of increased adverse events that include hypotension, syncope, electrolyte abnormalities and kidney injury or acute kidney failure.

The SPRINT trial, carried out in 102 centers across US, included 9,361 > 50 year oldpatients (mean agewas 68 years) with 130 to 180 mm Hg systolic blood pressure (mean 139.7 mm Hg) and high cardiovascular risk. Diabetics and patients with a history of stroke were excluded. The mean number of blood-pressure medications at baseline was 1.8, in both the intensive treatment group and the standard treatment group.

After one year, mean systolic blood pressure was 121.4 mm Hg in the intensive treatment group and 136.2 mm Hg in the standard treatment group; similar values were observed during the whole follow up period. The mean number of blood-pressure medications was 2.8 and 1.8, respectively.

There was a 25% reduction of relative risk and an absolute risk reduction of nearly 0.5% in the combined end point with the lowest blood pressure target.

More articles by this author

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...